NIPH Clinical Trials Search

JAPANESE
国立保健医療科学院
JRCT ID: jRCTs062220003

Registered date:12/04/2022

A study on safety and efficacy of high-flow nasal cannula attachable hydrogen gas generator for ARDS

Basic Information

Recruitment status Recruiting
Health condition(s) or Problem(s) studiedAcute respiratory distress syndrome
Date of first enrollment12/04/2022
Target sample size40
Countries of recruitment
Study typeInterventional
Intervention(s)Incidence of death and invasive mechanical ventilation from the start of hydrogen administration to 10 days

Outcome(s)

Primary OutcomeIncidence of death and invasive mechanical ventilation from the start of hydrogen administration to 10 days
Secondary Outcome1. Incidence of related adverse event from the start of hydrogen administration to 10 days 2. Respiratory function assessment: AaDO2, PaCO2, respiratory frequency, P/F ratio, Borg index 3. Inflammation assessment: WBC level, body temperature, IL-6, CRP, procalcitonin 4. Medical costs, ICU stay, duration of oxygen therapy requirement, duration of invasive mechanical ventilation.

Key inclusion & exclusion criteria

Age minimum>= 20age old
Age maximumNot applicable
GenderBoth
Include criteria1. Patients who are 20 years of age or older at the time of consent 2. Patients diagnosed with acute respiratory distress syndrome 3. Patients for whom high-flow nasal cannula is indicated 4. Patients who can perform hydrogen gas inhalation therapy within 48 hours after diagnosis of acute respiratory distress syndrome 5. Patients from whom written consent can be obtained either directly or through a surrogate decision maker.
Exclude criteria1. Patients with traumatic acute respiratory distress syndrome. 2. Patients who have received hydrogen gas inhalation within 1 month. 3. Patients with endotracheal intubation tube or tracheostomy tube. 4. Patients with bilateral nasal obstruction or nasal cavity damage. 5. Patients with severe chronic liver dysfunction equivalent to Grade C in the Child-Pugh classification. 6. Patients with chronic renal dysfunction requiring dialysis (Newly started hemodialysis due to the present illness is not treated as an exclusion criterion). 7. Patients who have started or will start invasive mechanical ventilation or ECMO. 8. Patients with chronic lung disorders requiring home oxygen therapy (Newly started oxygen therapy due to the present illness is not treated as an exclusion criterion). 9. Patients not tolerant to high-flow nasal cannula. 10. Patients with or suspected of having cancer. 11. Women who are pregnant or possibly pregnant. 12. Women who are breastfeeding. 13. Patients who have received other research or investigational drugs within the past 3 months. 14. Other patients who the investigator has determined to be ineligible for this study.

Related Information

Contact

Public contact
Name Toshiyuki Aokage
Address 2-5-1, Shikata-cho, Kita-ku, Okayama city, Okayama Okayama Japan 700-8558
Telephone +81-86-235-7427
E-mail t_aokage@okayama-u.ac.jp
Affiliation Okayama University Hospital
Scientific contact
Name Atsunori Nakao
Address 2-5-1, Shikata-cho, Kita-ku, Okayama Okayama Japan 700-8558
Telephone +81-86-235-7427
E-mail qq-nakao@okayama-u.ac.jp
Affiliation Okayama University Hospital